
Denmark’s Veloxis ended last week with a bit of good news, as it announced that FDA has granted Orphan Drug status for its drug Envarsus XR for prophylaxis of organ rejection in patients who convert from immediate-release tacrolimus.
"We view Orphan Drug status as the FDA's recognition of the differentiated profile and the unique ‘switch' indication of Envarsus XR compared to other tacrolimus products. We now look forward to making Envarsus XR available to conversion patients by the end of 2015," says William Polvino, M.D., president and chief executive officer of Veloxis, according to a press release.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app